Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 379

1.

Neuroblastoma Patients' KIR and KIR-Ligand Genotypes Influence Clinical Outcome for Dinutuximab-based Immunotherapy: A Report from the Children's Oncology Group.

Erbe AK, Wang W, Carmichael L, Kim K, Mendonça EA, Song Y, Hess D, Reville PK, London WB, Naranjo A, Hank JA, Diccianni MB, Reisfeld RA, Gillies SD, Matthay KK, Cohn SL, Hogarty MD, Maris JM, Park JR, Ozkaynak MF, Gilman AL, Yu AL, Sondel PM.

Clin Cancer Res. 2018 Jan 1;24(1):189-196. doi: 10.1158/1078-0432.CCR-17-1767. Epub 2017 Oct 2.

PMID:
28972044
2.

SOX2 regulates apoptosis through MAP4K4-survivin signaling pathway in human lung cancer cells.

Chen S, Li X, Lu D, Xu Y, Mou W, Wang L, Chen Y, Liu Y, Li X, Li LY, Liu L, Stupack D, Reisfeld RA, Xiang R, Li N.

Carcinogenesis. 2014 Mar;35(3):613-23. doi: 10.1093/carcin/bgt371. Epub 2013 Nov 14.

PMID:
24233838
3.

IMD-0354 targets breast cancer stem cells: a novel approach for an adjuvant to chemotherapy to prevent multidrug resistance in a murine model.

Gomez-Cabrero A, Wrasidlo W, Reisfeld RA.

PLoS One. 2013 Aug 27;8(8):e73607. doi: 10.1371/journal.pone.0073607. eCollection 2013.

4.

MicroRNA-19a-3p inhibits breast cancer progression and metastasis by inducing macrophage polarization through downregulated expression of Fra-1 proto-oncogene.

Yang J, Zhang Z, Chen C, Liu Y, Si Q, Chuang TH, Li N, Gomez-Cabrero A, Reisfeld RA, Xiang R, Luo Y.

Oncogene. 2014 Jun 5;33(23):3014-23. doi: 10.1038/onc.2013.258. Epub 2013 Jul 8.

PMID:
23831570
5.

Yes-associated protein (YAP) increases chemosensitivity of hepatocellular carcinoma cells by modulation of p53.

Bai N, Zhang C, Liang N, Zhang Z, Chang A, Yin J, Li Z, Luo N, Tan X, Luo N, Luo Y, Xiang R, Li X, Reisfeld RA, Stupack D, Lv D, Liu C.

Cancer Biol Ther. 2013 Jun;14(6):511-20. doi: 10.4161/cbt.24345.

6.

Intratumoral treatment of smaller mouse neuroblastoma tumors with a recombinant protein consisting of IL-2 linked to the hu14.18 antibody increases intratumoral CD8+ T and NK cells and improves survival.

Yang RK, Kalogriopoulos NA, Rakhmilevich AL, Ranheim EA, Seo S, Kim K, Alderson KL, Gan J, Reisfeld RA, Gillies SD, Hank JA, Sondel PM.

Cancer Immunol Immunother. 2013 Aug;62(8):1303-13. doi: 10.1007/s00262-013-1430-x. Epub 2013 May 10.

7.

The tumor microenvironment: a target for combination therapy of breast cancer.

Reisfeld RA.

Crit Rev Oncog. 2013;18(1-2):115-33. Review.

PMID:
23237555
8.

Tumor-associated macrophages regulate murine breast cancer stem cells through a novel paracrine EGFR/Stat3/Sox-2 signaling pathway.

Yang J, Liao D, Chen C, Liu Y, Chuang TH, Xiang R, Markowitz D, Reisfeld RA, Luo Y.

Stem Cells. 2013 Feb;31(2):248-58. doi: 10.1002/stem.1281.

9.

Intratumoral hu14.18-IL-2 (IC) induces local and systemic antitumor effects that involve both activated T and NK cells as well as enhanced IC retention.

Yang RK, Kalogriopoulos NA, Rakhmilevich AL, Ranheim EA, Seo S, Kim K, Alderson KL, Gan J, Reisfeld RA, Gillies SD, Hank JA, Sondel PM.

J Immunol. 2012 Sep 1;189(5):2656-64. doi: 10.4049/jimmunol.1200934. Epub 2012 Jul 27.

10.

SOX2 gene regulates the transcriptional network of oncogenes and affects tumorigenesis of human lung cancer cells.

Chen S, Xu Y, Chen Y, Li X, Mou W, Wang L, Liu Y, Reisfeld RA, Xiang R, Lv D, Li N.

PLoS One. 2012;7(5):e36326. doi: 10.1371/journal.pone.0036326. Epub 2012 May 15.

11.

Fra-1 promotes breast cancer chemosensitivity by driving cancer stem cells from dormancy.

Lu D, Chen S, Tan X, Li N, Liu C, Li Z, Liu Z, Stupack DG, Reisfeld RA, Xiang R.

Cancer Res. 2012 Jul 15;72(14):3451-6. doi: 10.1158/0008-5472.CAN-11-2536. Epub 2012 May 14.

12.

Anti-tumor and immunomodulatory activity of resveratrol in vitro and its potential for combining with cancer immunotherapy.

Soto BL, Hank JA, Darjatmoko SR, Polans AS, Yanke EM, Rakhmilevich AL, Seo S, Kim K, Reisfeld RA, Gillies SD, Sondel PM.

Int Immunopharmacol. 2011 Nov;11(11):1877-86. doi: 10.1016/j.intimp.2011.07.019. Epub 2011 Aug 18.

13.

Targeted therapeutic remodeling of the tumor microenvironment improves an HER-2 DNA vaccine and prevents recurrence in a murine breast cancer model.

Liao D, Liu Z, Wrasidlo WJ, Luo Y, Nguyen G, Chen T, Xiang R, Reisfeld RA.

Cancer Res. 2011 Sep 1;71(17):5688-96. doi: 10.1158/0008-5472.CAN-11-1264. Epub 2011 Jul 22.

14.

Downregulation of transcription factor SOX2 in cancer stem cells suppresses growth and metastasis of lung cancer.

Xiang R, Liao D, Cheng T, Zhou H, Shi Q, Chuang TS, Markowitz D, Reisfeld RA, Luo Y.

Br J Cancer. 2011 Apr 26;104(9):1410-7. doi: 10.1038/bjc.2011.94. Epub 2011 Apr 5. Erratum in: Br J Cancer. 2011 Jun 7;104(12):1931.

15.

Synthetic enzyme inhibitor: a novel targeting ligand for nanotherapeutic drug delivery inhibiting tumor growth without systemic toxicity.

Liao D, Liu Z, Wrasidlo W, Chen T, Luo Y, Xiang R, Reisfeld RA.

Nanomedicine. 2011 Dec;7(6):665-73. doi: 10.1016/j.nano.2011.03.001. Epub 2011 Mar 17.

PMID:
21419870
16.

The anti-tumor effect of resveratrol alone or in combination with immunotherapy in a neuroblastoma model.

Soto BL, Hank JA, Van De Voort TJ, Subramanian L, Polans AS, Rakhmilevich AL, Yang RK, Seo S, Kim K, Reisfeld RA, Gillies SD, Sondel PM.

Cancer Immunol Immunother. 2011 May;60(5):731-8. doi: 10.1007/s00262-011-0971-0. Epub 2011 Feb 22.

17.

Differential internalization of hu14.18-IL2 immunocytokine by NK and tumor cell: impact on conjugation, cytotoxicity, and targeting.

Buhtoiarov IN, Neal ZC, Gan J, Buhtoiarova TN, Patankar MS, Gubbels JA, Hank JA, Yamane B, Rakhmilevich AL, Reisfeld RA, Gillies SD, Sondel PM.

J Leukoc Biol. 2011 Apr;89(4):625-38. doi: 10.1189/jlb.0710422. Epub 2011 Jan 19.

18.

Genotypes of NK cell KIR receptors, their ligands, and Fcγ receptors in the response of neuroblastoma patients to Hu14.18-IL2 immunotherapy.

Delgado DC, Hank JA, Kolesar J, Lorentzen D, Gan J, Seo S, Kim K, Shusterman S, Gillies SD, Reisfeld RA, Yang R, Gadbaw B, DeSantes KB, London WB, Seeger RC, Maris JM, Sondel PM.

Cancer Res. 2010 Dec 1;70(23):9554-61. doi: 10.1158/0008-5472.CAN-10-2211. Epub 2010 Oct 8.

19.

Antitumor activity of hu14.18-IL2 in patients with relapsed/refractory neuroblastoma: a Children's Oncology Group (COG) phase II study.

Shusterman S, London WB, Gillies SD, Hank JA, Voss SD, Seeger RC, Reynolds CP, Kimball J, Albertini MR, Wagner B, Gan J, Eickhoff J, DeSantes KB, Cohn SL, Hecht T, Gadbaw B, Reisfeld RA, Maris JM, Sondel PM.

J Clin Oncol. 2010 Nov 20;28(33):4969-75. doi: 10.1200/JCO.2009.27.8861. Epub 2010 Oct 4.

20.

Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma.

Yu AL, Gilman AL, Ozkaynak MF, London WB, Kreissman SG, Chen HX, Smith M, Anderson B, Villablanca JG, Matthay KK, Shimada H, Grupp SA, Seeger R, Reynolds CP, Buxton A, Reisfeld RA, Gillies SD, Cohn SL, Maris JM, Sondel PM; Children's Oncology Group.

N Engl J Med. 2010 Sep 30;363(14):1324-34. doi: 10.1056/NEJMoa0911123.

21.

The role of proto-oncogene Fra-1 in remodeling the tumor microenvironment in support of breast tumor cell invasion and progression.

Luo YP, Zhou H, Krueger J, Kaplan C, Liao D, Markowitz D, Liu C, Chen T, Chuang TH, Xiang R, Reisfeld RA.

Oncogene. 2010 Feb 4;29(5):662-73. doi: 10.1038/onc.2009.308. Epub 2009 Dec 7.

22.

Cancer associated fibroblasts promote tumor growth and metastasis by modulating the tumor immune microenvironment in a 4T1 murine breast cancer model.

Liao D, Luo Y, Markowitz D, Xiang R, Reisfeld RA.

PLoS One. 2009 Nov 23;4(11):e7965. doi: 10.1371/journal.pone.0007965.

23.

Mouse models for melanoma: a personal perspective.

Becker JC, Houben R, Schrama D, Voigt H, Ugurel S, Reisfeld RA.

Exp Dermatol. 2010 Feb;19(2):157-64. doi: 10.1111/j.1600-0625.2009.00986.x. Epub 2009 Oct 22. Review.

24.

Vaccination against TIE2 reduces atherosclerosis.

Hauer AD, Habets KL, van Wanrooij EJ, de Vos P, Krueger J, Reisfeld RA, van Berkel TJ, Kuiper J.

Atherosclerosis. 2009 Jun;204(2):365-71. doi: 10.1016/j.atherosclerosis.2008.09.039. Epub 2008 Oct 17.

PMID:
19022447
25.

Intratumoral immunocytokine treatment results in enhanced antitumor effects.

Johnson EE, Lum HD, Rakhmilevich AL, Schmidt BE, Furlong M, Buhtoiarov IN, Hank JA, Raubitschek A, Colcher D, Reisfeld RA, Gillies SD, Sondel PM.

Cancer Immunol Immunother. 2008 Dec;57(12):1891-902. doi: 10.1007/s00262-008-0519-0. Epub 2008 Apr 26.

26.

Oral DNA vaccines target the tumor vasculature and microenvironment and suppress tumor growth and metastasis.

Xiang R, Luo Y, Niethammer AG, Reisfeld RA.

Immunol Rev. 2008 Apr;222:117-28. doi: 10.1111/j.1600-065X.2008.00613.x. Review.

PMID:
18363997
27.

A Legumain-based minigene vaccine targets the tumor stroma and suppresses breast cancer growth and angiogenesis.

Lewēn S, Zhou H, Hu HD, Cheng T, Markowitz D, Reisfeld RA, Xiang R, Luo Y.

Cancer Immunol Immunother. 2008 Apr;57(4):507-15. Epub 2007 Sep 5.

PMID:
17786443
28.

Immunological tumor destruction in a murine melanoma model by targeted LTalpha independent of secondary lymphoid tissue.

Schrama D, Voigt H, Eggert AO, Xiang R, Zhou H, Schumacher TN, Andersen MH, thor Straten P, Reisfeld RA, Becker JC.

Cancer Immunol Immunother. 2008 Jan;57(1):85-95. Epub 2007 Jun 29.

PMID:
17605009
29.

Vaccination against VEGFR2 attenuates initiation and progression of atherosclerosis.

Hauer AD, van Puijvelde GH, Peterse N, de Vos P, van Weel V, van Wanrooij EJ, Biessen EA, Quax PH, Niethammer AG, Reisfeld RA, van Berkel TJ, Kuiper J.

Arterioscler Thromb Vasc Biol. 2007 Sep;27(9):2050-7. Epub 2007 Jun 28.

30.

Fractalkine (CX3CL1)- and interleukin-2-enriched neuroblastoma microenvironment induces eradication of metastases mediated by T cells and natural killer cells.

Zeng Y, Huebener N, Fest S, Weixler S, Schroeder U, Gaedicke G, Xiang R, Schramm A, Eggert A, Reisfeld RA, Lode HN.

Cancer Res. 2007 Mar 1;67(5):2331-8.

31.

DNA vaccination against VEGF receptor 2 reduces atherosclerosis in LDL receptor-deficient mice.

Petrovan RJ, Kaplan CD, Reisfeld RA, Curtiss LK.

Arterioscler Thromb Vasc Biol. 2007 May;27(5):1095-100. Epub 2007 Feb 15.

32.

FLK-1-based minigene vaccines induce T cell-mediated suppression of angiogenesis and tumor protective immunity in syngeneic BALB/c mice.

Luo Y, Markowitz D, Xiang R, Zhou H, Reisfeld RA.

Vaccine. 2007 Feb 9;25(8):1409-15. Epub 2006 Nov 7.

33.

A novel DNA vaccine encoding PDGFRbeta suppresses growth and dissemination of murine colon, lung and breast carcinoma.

Kaplan CD, Krüger JA, Zhou H, Luo Y, Xiang R, Reisfeld RA.

Vaccine. 2006 Nov 17;24(47-48):6994-7002. Epub 2006 Jun 5.

PMID:
17050049
34.

Adenovirus fiber shaft contains a trimerization element that supports peptide fusion for targeted gene delivery.

Li J, Lad S, Yang G, Luo Y, Iacobelli-Martinez M, Primus FJ, Reisfeld RA, Li E.

J Virol. 2006 Dec;80(24):12324-31. Epub 2006 Oct 4.

35.
36.

Characterization of stem cell-like cancer cells in immune-competent mice.

Kruger JA, Kaplan CD, Luo Y, Zhou H, Markowitz D, Xiang R, Reisfeld RA.

Blood. 2006 Dec 1;108(12):3906-12. Epub 2006 Aug 15.

37.

Targeting tumor-associated macrophages as a novel strategy against breast cancer.

Luo Y, Zhou H, Krueger J, Kaplan C, Lee SH, Dolman C, Markowitz D, Wu W, Liu C, Reisfeld RA, Xiang R.

J Clin Invest. 2006 Aug;116(8):2132-2141.

38.

Targeting tumor-associated fibroblasts improves cancer chemotherapy by increasing intratumoral drug uptake.

Loeffler M, Krüger JA, Niethammer AG, Reisfeld RA.

J Clin Invest. 2006 Jul;116(7):1955-62. Epub 2006 Jun 22. Erratum in: J Clin Invest. 2009 Feb;119(2):421.

39.

A simplified cloning strategy for the generation of an endothelial cell selective recombinant adenovirus vector.

Mahanivong C, Krüger JA, Bian D, Reisfeld RA, Huang S.

J Virol Methods. 2006 Jul;135(1):127-35. Epub 2006 Apr 3.

PMID:
16581140
40.

Endoglin (CD105) is a target for an oral DNA vaccine against breast cancer.

Lee SH, Mizutani N, Mizutani M, Luo Y, Zhou H, Kaplan C, Kim SW, Xiang R, Reisfeld RA.

Cancer Immunol Immunother. 2006 Dec;55(12):1565-74. Epub 2006 Mar 25.

PMID:
16565828
41.

A phase I clinical trial of the hu14.18-IL2 (EMD 273063) as a treatment for children with refractory or recurrent neuroblastoma and melanoma: a study of the Children's Oncology Group.

Osenga KL, Hank JA, Albertini MR, Gan J, Sternberg AG, Eickhoff J, Seeger RC, Matthay KK, Reynolds CP, Twist C, Krailo M, Adamson PC, Reisfeld RA, Gillies SD, Sondel PM; Children's Oncology Group.

Clin Cancer Res. 2006 Mar 15;12(6):1750-9.

42.

Antibody targeted drugs as cancer therapeutics.

Schrama D, Reisfeld RA, Becker JC.

Nat Rev Drug Discov. 2006 Feb;5(2):147-59. Review.

PMID:
16424916
43.

A DNA-based cancer vaccine enhances lymphocyte cross talk by engaging the NKG2D receptor.

Zhou H, Luo Y, Kaplan CD, Krüger JA, Lee SH, Xiang R, Reisfeld RA.

Blood. 2006 Apr 15;107(8):3251-7. Epub 2005 Dec 20.

44.

Intralesional targeted alpha therapy for metastatic melanoma.

Allen BJ, Raja C, Rizvi S, Li Y, Tsui W, Graham P, Thompson JF, Reisfeld RA, Kearsley J.

Cancer Biol Ther. 2005 Dec;4(12):1318-24. Epub 2005 Dec 18.

PMID:
16322682
45.

Therapeutic efficacy of tumor-targeted IL2 in LTalpha(-/-) mice depends on conditioned T cells.

Schrama D, Voigt H, Eggert AO, Xiang R, Reisfeld RA, Becker JC.

Cancer Immunol Immunother. 2006 Jul;55(7):861-6. Epub 2005 Sep 13.

PMID:
16158274
46.

Inhibition of alpha(v)beta3 integrin survival signaling enhances antiangiogenic and antitumor effects of radiotherapy.

Abdollahi A, Griggs DW, Zieher H, Roth A, Lipson KE, Saffrich R, Gröne HJ, Hallahan DE, Reisfeld RA, Debus J, Niethammer AG, Huber PE.

Clin Cancer Res. 2005 Sep 1;11(17):6270-9.

47.

DNA-based vaccines activate innate and adaptive antitumor immunity by engaging the NKG2D receptor.

Zhou H, Luo Y, Lo JF, Kaplan CD, Mizutani M, Mizutani N, Lee JD, Primus FJ, Becker JC, Xiang R, Reisfeld RA.

Proc Natl Acad Sci U S A. 2005 Aug 2;102(31):10846-51. Epub 2005 Jul 22.

48.

Immunostimulatory effects of low-dose cyclophosphamide are controlled by inducible nitric oxide synthase.

Loeffler M, Krüger JA, Reisfeld RA.

Cancer Res. 2005 Jun 15;65(12):5027-30.

49.

T cell-mediated suppression of angiogenesis results in tumor protective immunity.

Zhou H, Luo Y, Mizutani M, Mizutani N, Reisfeld RA, Xiang R.

Blood. 2005 Sep 15;106(6):2026-32. Epub 2005 May 26.

50.

Tid1 is required for T cell transition from double-negative 3 to double-positive stages.

Lo JF, Zhou H, Fearns C, Reisfeld RA, Yang Y, Lee JD.

J Immunol. 2005 May 15;174(10):6105-12.

Supplemental Content

Loading ...
Support Center